<?xml version='1.0' encoding='utf-8'?>
<document id="18074029"><sentence text="A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination."><entity charOffset="66-76" id="DDI-PubMed.18074029.s1.e0" text="amantadine" /><entity charOffset="81-92" id="DDI-PubMed.18074029.s1.e1" text="oseltamivir" /><pair ddi="false" e1="DDI-PubMed.18074029.s1.e0" e2="DDI-PubMed.18074029.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18074029.s1.e0" e2="DDI-PubMed.18074029.s1.e1" /></sentence><sentence text="The threat of potential pandemic influenza requires a reevaluation of licensed therapies for the prophylaxis or treatment of avian H5N1 infection that may adapt to man" /><sentence text=" Among the therapies considered for use in pandemic influenza is the co-administration of ion channel and neuraminidase inhibitors, both to potentially increase efficacy as well as to decrease the emergence of resistant isolates" /><sentence text=" To better understand the potential for drug interactions, a cross-over, randomized, open-label trial was conducted with amantadine, 100 mg po bid, and oseltamivir, 75 mg po bid, given alone or in combination for 5 days"><entity charOffset="121-131" id="DDI-PubMed.18074029.s4.e0" text="amantadine" /><entity charOffset="152-163" id="DDI-PubMed.18074029.s4.e1" text="oseltamivir" /><pair ddi="false" e1="DDI-PubMed.18074029.s4.e0" e2="DDI-PubMed.18074029.s4.e0" /><pair ddi="false" e1="DDI-PubMed.18074029.s4.e0" e2="DDI-PubMed.18074029.s4.e1" /></sentence><sentence text=" Each subject (N = 17) served as their own control and was administered each drug alone or in combination, with appropriate wash-out"><entity charOffset="15-16" id="DDI-PubMed.18074029.s5.e0" text="N" /></sentence><sentence text=" Co-administration with oseltamivir had no clinically significant effect on the pharmacokinetics (PK) of amantadine [mean ratios (90% CI) for AUC(0-12) 0"><entity charOffset="24-35" id="DDI-PubMed.18074029.s6.e0" text="oseltamivir" /><entity charOffset="105-115" id="DDI-PubMed.18074029.s6.e1" text="amantadine" /><pair ddi="false" e1="DDI-PubMed.18074029.s6.e0" e2="DDI-PubMed.18074029.s6.e0" /><pair ddi="false" e1="DDI-PubMed.18074029.s6.e0" e2="DDI-PubMed.18074029.s6.e1" /></sentence><sentence text="93 (0" /><sentence text="89, 0" /><sentence text="98) and C(max) 0" /><sentence text="96 (0" /><sentence text="90, 1" /><sentence text="02)]" /><sentence text=" Similarly, amantadine co-administration did not affect oseltamivir PK [AUC(0-12) 0"><entity charOffset="12-22" id="DDI-PubMed.18074029.s13.e0" text="amantadine" /><entity charOffset="56-67" id="DDI-PubMed.18074029.s13.e1" text="oseltamivir" /><pair ddi="false" e1="DDI-PubMed.18074029.s13.e0" e2="DDI-PubMed.18074029.s13.e0" /><pair ddi="false" e1="DDI-PubMed.18074029.s13.e0" e2="DDI-PubMed.18074029.s13.e1" /></sentence><sentence text="92 (0" /><sentence text="86, 0" /><sentence text="99) and C(max) 0" /><sentence text="85 (0" /><sentence text="73, 0" /><sentence text="99)] or the PK of the metabolite, oseltamivir carboxylate [AUC(0-12) 0"><entity charOffset="34-57" id="DDI-PubMed.18074029.s19.e0" text="oseltamivir carboxylate" /></sentence><sentence text="98 (0" /><sentence text="95, 1" /><sentence text="02) and C(max) 0" /><sentence text="95 (0" /><sentence text="89, 1" /><sentence text="01)]" /><sentence text=" In this small trial there was no evidence of an increase in adverse events" /><sentence text=" Although many more subjects would need to be studied to rule out a synergistic increase in adverse events, the combination in this small human drug-drug interaction trial appears safe and without pharmacokinetic consequences" /><sentence text="" /><sentence text="ClinicalTrials" /><sentence text="gov NCT00416962"><entity charOffset="4-26" id="DDI-PubMed.18074029.s30.e0" text="N" /></sentence><sentence text="" /></document>